Browsing Tag
Roche Holding AG
16 posts
Eisai’s etalanetug earns FDA Fast Track status, signaling new hope in Alzheimer’s therapy
Eisai’s etalanetug gets FDA Fast Track for Alzheimer’s, signaling a major shift toward tau-targeting therapies. Find out what this means for investors.
Why Henlius Biotech’s HLX43 deal talks with Johnson & Johnson and Roche are shaking up global oncology
Henlius Biotech is negotiating with Johnson & Johnson and Roche on HLX43 rights. Learn how this deal could reshape oncology licensing and investor sentiment.
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market.
Atezolizumab slashes colon cancer recurrence by 50% in ATOMIC trial: ASCO 2025 breakthrough
Genentech’s Tecentriq cuts recurrence risk by 50% in dMMR colon cancer, setting the stage for new adjuvant approvals after ATOMIC trial success.
MicroAlgo crashes 20%, Trump Media slips again—here’s why markets panicked
Explore why 25 top U.S.-listed stocks tumbled on April 2 as Trump’s tariff strategy ignited fears of inflation, recession, and global retaliation.
How Roche’s new deal with LumiraDx will transform Point of Care testing forever
Roche Holding AG has finalised its acquisition of LumiraDx’s innovative Point of Care technology, a strategic move aimed…